This economic evaluation results were consistent with the previous results of first-line PD-1/PD-L1 antibodies for NSCLC from the perspective of China's healthcare system, including camrelizumab ($63,080/QALYs) (20), pembrolizumab ($92,533/QALYs) (21), atezolizumab ($325,328/QALYs) (22). The gene discussed is CD274; the disease is non-small cell lung carcinoma.